MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jdv.20670

Медицинская библиотека · Journal of the European Academy of Dermatology and Venereology : JEADV · 2025

Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study.

Preuß Sophie L, Bieber Katja, Vorobyev Artem, Recke Andreas, Moderegger Eva Lotta, Zirpel Henner, Gaffal Evelyn, Thaçi Diamant, Kridin Khalaf, Ludwig Ralf J

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Type 2 chronic inflammatory diseases (T2IDs) are highly prevalent among women of reproductive age. Dupilumab, a monoclonal antibody, is increasingly used to treat T2IDs. While dupilumab is not approved during pregnancy, smaller studies suggest no increased risk of pregnancy complications (adverse pregnancy outcomes (APOs)). Additional data are required to better assess the drug's safety during pregnancy.

OBJECTIVES

To retrospectively assess the risk of APOs in dupilumab-treated pregnant women in a large real-world database.

METHODS

Pregnant women with T2ID and dupilumab treatment during pregnancy were retrieved from the US Collaborative Network of TriNetX. Pregnant women with T2ID and without dupilumab treatment served as controls. Propensity score matching (PSM) for demographics, diagnoses, medications and putative APO risk factors was employed. Outcomes analysed included various maternal pregnancy complications, including premature obstetric labour, pregnancy-induced hypertension, gestational diabetes, puerperal infections and spontaneous abortion. Survival analyses were assessed using the Kaplan-Meier method, outcome differences the log-rank test and hazard ratios (HR) the Cox regression model.

RESULTS

During pregnancy, 293 women were exposed to dupilumab. Following PSM, no increased risks for APOs were noted. Of note, reduced risks for premature obstetric labour (HR: 0.11, confidence interval (CI): 0.03-0.45, p = 0.0002) and 'any APO' (HR: 0.53, CI: 0.33-0.84, p = 0.0067) in the dupilumab-treated group were found. Furthermore, no difference in risks for any APO was noted between dupilumab-treated and untreated women up to 6 months before pregnancy or during the postpartum period.

CONCLUSIONS

This large-scale propensity-matched retrospective cohort study suggests a favourable safety profile of dupilumab during pregnancy. Given the difficulties of prospective studies during pregnancy, it provides valuable insights, though further studies are needed to confirm these findings and explore causal relationships.

Для цитирования: Preuß Sophie L, Bieber Katja, Vorobyev Artem, Recke Andreas, Moderegger Eva Lotta, Zirpel Henner, Gaffal Evelyn, Thaçi Diamant, Kridin Khalaf, Ludwig Ralf J. Dupilumab shows no elevated risk for maternal adverse pregnancy outcomes: A propensity-matched cohort study.. Journal of the European Academy of Dermatology and Venereology : JEADV. 2025. DOI: 10.1111/jdv.20670.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.